The therapeutic potential of glycine transporter-1 inhibitors

Expert Opinion on Investigational Drugs

Volumn 13, Issue 5, 2004, Pages 515-521

  Sur, Cyrille ^a   Kinney, Gene G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dementia; Glycine; Glycine transporter 1; N methyl D aspartate; Schizophrenia

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; ALX 5407; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARRIER PROTEIN; CLOZAPINE; COCAINE; CYCLOSERINE; DEXTRO SERINE; GLYCINE; GLYCINE TRANSPORTER 1; GLYCYLDODECYLAMIDE; KETAMINE; LYSERGIDE; N [3 (4' FLUOROPHENYL) 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ORG 24598; PHENCYCLIDINE; PROTEIN INHIBITOR; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SARCOSINE; UNCLASSIFIED DRUG;

ATAXIA; CATAPLEXY; COGNITIVE DEFECT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; MOTOR DYSFUNCTION; MOUSE; NEUROTOXICITY; NONHUMAN; PAIN; PSYCHOSIS; RAT; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE THRESHOLD; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNAPSE; TARDIVE DYSKINESIA; WEIGHT GAIN;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; DRUG THERAPY; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS;

EID: 2642557822     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.5.515     Document Type: Review

References (46)

1. Aprison MH: The discovery of the neurotransmitter role of glycine. In: Glycine Neurotransmission. OP Ottersen, J Storm-Mathisen (Eds), John Wiley and Sons, Chichester, UK (1990):1-23.
2. Johnson JW, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325(6104):529-531.
3. Betz H: Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron (1990) 5(4):383-392.
4. Bergeron R, Meyer TM, Coyle JT, Greene RW: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA (1998) 95(26): 15730-15734.
5. Danysz W, Parsons AC: Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. (1998) 50(4): 597-664.
6. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL: Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron (1992) 8(5):927-935.
7. Borowsky B, Mezey E, Hoffman BJ: Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron (1993) 10(5):851-863.
8. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N: Cloning and expression of a spinal cord- and brain-specific glycine transporter with novel structural features. J. Biol. Chem. (1993) 268(30):22802-22808.
9. Kim KM, Kingsmore SF, Han H et al.: Cloning of the human glycine transporter Type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene. Mol. Pharmacol. (1994) 45(4):608-617.
10. Morrow JA, Collie IT, Dunbar DR, Walker GB, Shahid M, Hill DR: Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localisation of the gene in the human genome. FEBS Lett. (1998) 439(3):334-340.
11. Nelson N: The family of Na+/Cl- neurotransmitter transporters. J. Neurochem. (1998) 71(5):1785-1803.
12. Zafra F, Gomeza J, Olivares L, Aragon C, Gimenez C: Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur. J. Neurosci. (1995) 7(6):1342-1352.
13. Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J: Glycine transporters are differentially expressed among CNS cells. J. Neurosci. (1995) 15(5Pt. 2):3952-3969.
14. Supplisson S, Bergman C: Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J. Neurosci. (1997) 17(12):4580-4590.
15. Atkinson BN, Bell SC, De Vivo M et al.: ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol. Pharmacol. (2001) 60(6):1414-1420.
16. Aubrey KR, Vandenberg RJ: N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. (2001) 134(7):1429-1436.
17. Mallorga PJ, Williams JB, Jacobson M et al.: Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4′-fluorophenyl)-3-(4′phenylphenoxy)propyl] sarcosine. Neuropharmacology (2003) 45(5):585-593.
18. Berger AJ, Dieudonne S, Ascher P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. (1998) 80(6):3336-3340.
19. Kinney GG, Sur C, Burno M et al.: The glycine transporter Type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. (2003) 23(20):7586-7591.
20. Chen L, Muhlhauser M, Yang CR: Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. (2003) 89(2):691-703.
21. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. (1991) 148(10):1301-1308.
22. Millan MJ: N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr. Drug. Target CNS Neurol. Disord. (2002) 1(2):191-213.
23. Olney JW, Newcomer JW, Farber NB: NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. (1999) 33(6):523-533.
24. Toth E, Lajtha A: Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. (1986) 11(3):393-400.
25. Javitt DC, Sershen H, Hashim A, Lajtha A: Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology (1997) 17(3):202-204.
26. McCaughran J, Mahjubi E, Decena E, Hitzemann R: Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (1997) 134(2):131-139.
27. Klitenick MA, Atkinson BN, Baker DA et al.: Development and characterization of GlyT1-selective glycine reuptake inhibitors. American College of Neuropsychopharmacology 40th Annual Meeting. Waikoloa, Hawaii (2001).
28. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL: Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol. Psychiatry (2003) 54(11):1162-1170.
29. Lipska BK, Weinberger DR: Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res. Dev. Brain Res. (1993) 75(2):213-222.
30. Sumioshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY: Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. (2004) 7(1):1-8.
31. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP: Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry (1994) 151(8):1234-1236.
32. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D: Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry (1996) 169(5):610-617
33. Javitt DC, Silipo G, Cienfuegos A et al.: Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. (2001) 4(4):385-391.
34. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry (1999) 56(1):29-36.
35. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC: High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry (2004) 55(2):165-171.
36. Tsai G, Lane H, Young PJ, Lane N, Chong M: Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry (2004) I55(5):452-456.
37. Harsing LG Jr, Gacsalyi I, Szabo G et al.: The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol. Biochem. Behav. (2003) 74(4):811-825.
38. Didriksen M, Hertel P, Mork A: Antipsychotic potential of the GlyT-1 inhibitor NFPS. Society for Neuroscience 2002 Annual Meeting. Washington, DC (2002).
39. Gorfinkel Y, Martina M, Schmidt CJ, Bergeron R: Blockade of the glycine transporter Type 1 enhances hippocampal LTP. Society for Neuroscience 2003 Annual Meeting. Washington, DC (2003).
40. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI: D-Cycloserine enhances implicit memory in Alzheimer patients. Neurology (1996) 46(2):420-424.
41. Tsai GE, Falk WE, Gunther J, Coyle JT: Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am. J. Psychiatry. (1999) 156(3):467-469.
42. Gomeza J, Hulsmann S, Ohno K et al.: Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron (2003) 40(4):785-796.
43. Billups D, Attwell D: Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse. Eur. J. Neurosci. (2003) 18(11):2975-8290.
44. Pow DV: Amino acids and their transporters in the retina. Neurochem. Int. (2001) 38(6):463-484.
45. Brown A, Carlyle I, Clark J et al.: Discovery and SAR of org 24598-a selective glycine uptake inhibitor. Bioorg. Med. Chem. Lett. (2001) 11(15):2007-2009.
46. Lowe JA 3rd, Drozda SE, Fisher K et al.: [3H]-(R)-NPTS, a radioligand for the Type 1 glycine transporter. Bioorg. Med. Chem. Lett. (2003) 13(7):1291-1292.